Monte Rosa Therapeutics, Inc.
GLUE
$16.86
$1.459.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -44.95% | -72.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -44.95% | -72.69% | |||
| Cost of Revenue | 19.30% | -3.54% | |||
| Gross Profit | -273.99% | -110.67% | |||
| SG&A Expenses | 14.33% | -10.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.05% | -5.25% | |||
| Operating Income | -112.00% | -135.32% | |||
| Income Before Tax | -172.69% | -123.26% | |||
| Income Tax Expenses | -364.97% | 45.86% | |||
| Earnings from Continuing Operations | -120.26% | -126.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -120.26% | -126.22% | |||
| EBIT | -112.00% | -135.32% | |||
| EBITDA | -129.95% | -129.14% | |||
| EPS Basic | -119.72% | -126.21% | |||
| Normalized Basic EPS | -171.92% | -123.28% | |||
| EPS Diluted | -120.00% | -126.32% | |||
| Normalized Diluted EPS | -171.92% | -123.51% | |||
| Average Basic Shares Outstanding | 0.26% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.26% | -0.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||